Current treatment status-Undergoing active treatment-Partial response - Page 2 of 7 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Partial response Posts on Medivizor

How effective is long-term brentuximab vedotin treatment for patients with recurrent or non-responding Hodgkin’s lymphoma?

Posted by on Jan 12, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated long-term treatment with brentuximab vedotin (Adcetris) for patients with Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. This study concluded that this treatment had a long-term benefit for some patients. Some background Most patients with HL respond well to initial treatment....

Read More

Evaluating isatuximab for patients with recurrent or non-responding multiple myeloma

Posted by on Jan 8, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study examined the effectiveness and safety of isatuximab plus PD (pomalidomide, dexamethasone) for patients with multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that isatuximab was well-tolerated and significantly improved survival outcomes for these patients. Some...

Read More

Evaluating pembrolizumab for patients with primary mediastinal large B-cell lymphoma that has come back or stopped responding to treatment

Posted by on Nov 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) for patients with primary mediastinal large B-cell lymphoma (PMBCL) that has come back or stopped responding to treatment. This study concluded that pembrolizumab was safe and effective for these patients. Some background PMBCL is one rare and aggressive type...

Read More

Is tislelizumab safe and effective for patients with relapsed or refractory classical Hodgkin’s lymphoma?

Posted by on Oct 12, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined how effective and safe tislelizumab (BGB-A317) is for patients with relapsed or refractory classical Hodgkin's lymphoma (cHL). The authors concluded that most patients responded to tislelizumab but also experienced side effects. Some background cHL is often treated with chemotherapy or stem cell...

Read More

Evaluating combination CAR-T cell therapy for recurrent or treatment-resistant multiple myeloma

Posted by on Oct 6, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of combining two T-cell therapies for multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that this treatment showed promising effectiveness for these patients. Some background Treatment for patients with MM that has come back (relapsed)...

Read More

Looking for patients with relapsed or unresponsive multiple myeloma to try allogeneic CAR-T cell therapy

Posted by on Sep 30, 2019 in Multiple Myeloma | 0 comments

In a nutshell This trial is evaluating the safety and effectiveness of allogeneic CAR-T cell therapy (ALLO-715) in patients with multiple myeloma (MM) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This trial is recruiting in Denver, CO. The details Chimeric...

Read More

Evaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia

Posted by on Sep 13, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...

Read More

Evaluating nivolumab plus brentuximab vedotin for patients with relapsed or unresponsive primary mediastinal large B-cell lymphoma

Posted by on Aug 17, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated nivolumab (Opdivo) plus brentuximab vedotin (Adcetris) in patients with relapsed or unresponsive primary mediastinal B-cell lymphoma (PMBCL). This study concluded that this combination is promising and was well-tolerated. Some background PMBCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL)....

Read More

Looking for patients with relapsed or unresponsive classical Hodgkin lymphoma to test a new treatment combination

Posted by on Jul 21, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study is evaluating how well a new chemoimmunotherapy regimen works in treating patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer after treatment. This study...

Read More

Using alpha-interferon to treat residual chronic myeloid leukemia after transplantation

Posted by on Jul 14, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of interferon-alpha (IntronA) treatment in patients with chronic myeloid leukemia (CML) with residual disease after transplantation. Researchers found that this treatment may be useful in patients with signs of disease after transplant. Some background Chronic myeloid leukemia is a cancer...

Read More

Evaluating high-dose etoposide before stem cell transplantation for patients with unresponsive diffuse large B cell lymphoma

Posted by on Jun 16, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of patients with unresponsive diffuse B-cell lymphoma (DLBCL) after treatment with high-dose etoposide (Etopophos) and a stem cell transplant (SCT). This study concluded that this regimen was effective for some of these patients, namely those who responded to etoposide treatment. Some background DLBCL is...

Read More